179 related articles for article (PubMed ID: 37229799)
41. Treatment of multiple sclerosis with anti-CD20 antibodies.
Barun B; Bar-Or A
Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
[TBL] [Abstract][Full Text] [Related]
42. Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis.
Tacke S; Chunder R; Schropp V; Urich E; Kuerten S
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328594
[TBL] [Abstract][Full Text] [Related]
43. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
[TBL] [Abstract][Full Text] [Related]
44. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
45. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.
Alba Suárez EM; Tallón Barranco A; Puertas Muñoz I; Chamorro Hernández B; Robles Marhuenda Á
Neurologia (Engl Ed); 2023 Sep; 38(7):463-466. PubMed ID: 37659836
[TBL] [Abstract][Full Text] [Related]
46. Colitis associated with biological agents.
Freeman HJ
World J Gastroenterol; 2012 Apr; 18(16):1871-4. PubMed ID: 22563166
[TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder.
Ciplea AI; Langer-Gould A; de Vries A; Schaap T; Thiel S; Ringelstein M; Gold R; Hellwig K
Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32327455
[TBL] [Abstract][Full Text] [Related]
48. De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center.
Eckmann JD; Chedid V; Quinn KP; Bonthu N; Nehra V; Raffals LE
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):252-253. PubMed ID: 30905719
[TBL] [Abstract][Full Text] [Related]
49. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
50. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
51. A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis.
Sabahi Z; Daei Sorkhabi A; Sarkesh A; Naseri A; Asghar-Rezaei N; Talebi M
Int Immunopharmacol; 2023 Jul; 120():110266. PubMed ID: 37209514
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal antibodies in treatment of multiple sclerosis.
Rommer PS; Dudesek A; Stüve O; Zettl UK
Clin Exp Immunol; 2014 Mar; 175(3):373-84. PubMed ID: 24001305
[TBL] [Abstract][Full Text] [Related]
53. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
54. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
55. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases.
Oksbjerg NR; Nielsen SD; Blinkenberg M; Magyari M; Sellebjerg F
Mult Scler Relat Disord; 2021 Jul; 52():102988. PubMed ID: 33979772
[TBL] [Abstract][Full Text] [Related]
56. Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
Baber U; Bouley A; Egnor E; Sloane JA
J Neurol; 2018 Oct; 265(10):2342-2345. PubMed ID: 30109480
[TBL] [Abstract][Full Text] [Related]
57. Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
[TBL] [Abstract][Full Text] [Related]
58. Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes.
Kow CS; Ramachandram DS; Hasan SS; Thiruchelvam K
Inflammopharmacology; 2023 Dec; 31(6):3339-3355. PubMed ID: 37804462
[TBL] [Abstract][Full Text] [Related]
59. Ocrelizumab: its efficacy and safety in multiple sclerosis.
Juanatey A; Blanco-Garcia L; Tellez N
Rev Neurol; 2018 Jun; 66(12):423-433. PubMed ID: 29897610
[TBL] [Abstract][Full Text] [Related]
60. Efficiency of antibody therapy in demyelinating diseases.
Akaishi T; Nakashima I
Int Immunol; 2017 Jul; 29(7):327-335. PubMed ID: 28910968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
